Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4288466 | 0.86 | SMN1; SMN2 (0.47) | ALDH1A1POLBMAPTKMT2ALMNA | |
| SCHEMBL8104093 | 0.71 | KMT2A (0.49) | ALDH1A1POLBMAPTKMT2ALMNA | |
| SCHEMBL7088107 | 0.70 | ROCK2 (0.58) | ALDH1A1POLBMAPTKMT2ALMNA | |
| SCHEMBL990297 | 0.69 | ALDH1A1 (0.60) | ALDH1A1POLBMAPTKMT2ALMNA | |
| SCHEMBL6246751 | 0.69 | KMT2A (0.45) | ALDH1A1POLBMAPTKMT2ALMNA | |
| SCHEMBL27874614 | 0.68 | ALDH1A1 (0.55) | ALDH1A1MAPTKMT2ALMNATP53 | |
| SCHEMBL6906376 | 0.67 | CACNA1H (0.48) | POLBMAPTKMT2ALMNAMEN1 | |
| SCHEMBL5657581 | 0.67 | MEN1 (0.70) | ALDH1A1POLBMAPTKMT2ALMNA | |
| SCHEMBL8988041 | 0.67 | POLB (0.57) | ALDH1A1POLBMAPTKMT2ALMNA | |
| SCHEMBL6246258 | 0.67 | SRD5A2 (0.58) | ALDH1A1MAPTKMT2AMEN1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156582-A1 | Pyrazole Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | claimed |
| EP-1847531-A1 | PYRAZOLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-10-24 | — | — | EP | claimed |
| US-20090156582-A1 | Pyrazole Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| EP-1847531-A1 | PYRAZOLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156582-A1 | Pyrazole Compound | GSK3B, GSK3A, GSKIP | ALDH1A1 694/4885POLB 3501/4885MAPT 868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.